---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017587"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:47:24.959195+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers

## Summary
- EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
- Detected 100% of cancers; overall sensitivity/specificity 85% each; estimated NPV 98% and PPV 39%.
- Study published in American Journal of Gastroenterology; investigators from Mayo Clinic, Johns Hopkins, Cleveland Clinic.
- Company plans to seek Medicare coverage via MolDX pre-submission meeting and formal technical assessment.

## SEC filing metadata
- accession: 0001493152-24-017587
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/0001493152-24-017587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017587
- JSON: https://secwatch.observer/filing/0001493152-24-017587.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.